ReviewCurrent allergy and asthma reports2016
Biomarkers of Airway Type-2 Inflammation and Integrating Complex Phenotypes to Endotypes in Asthma.
Review in Current allergy and asthma reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 16 citations in OpenAlex.
- Epithelial Lining Fluid Cystatin SN is a Noninvasive Biomarker for Predicting Type 2 Chronic Rhinosinusitis.Allergy · 2025Article
- The management of type 2 inflammatory respiratory diseases: a Chinese expert consensus [2024].Journal of thoracic disease · 2025Review
- The Role of Vitamins in the Pathogenesis of Asthma.International journal of molecular sciences · 2023Review
- Addressing the unmet needs in patients with type 2 inflammatory diseases: when quality of life can make a difference.Frontiers in allergy · 2023Article
- High-dimensional profiling clusters asthma severity by lymphoid and non-lymphoid status.Cell reports · 2021Article
- Refractory airway type 2 inflammation in a large subgroup of asthmatic patients treated with inhaled corticosteroids.The Journal of allergy and clinical immunology · 2019Article
- Article
- Small molecule targeting of the STAT5/6 Src homology 2 (SH2) domains to inhibit allergic airway disease.The Journal of biological chemistry · 2018Article
- Quality of Life in Patients With Type 2 Inflammatory Asthma.Open respiratory archivesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewOver the past decade, the most important advance in the field of asthma has been the widespread recognition that asthma is a heterogeneous disease driven by multiple molecular processes. RECENT
findingsThe most well-established molecular mechanism in asthma is increased airway type-2 inflammation, and consequently, non-invasive biomarkers of increased airway type-2 inflammation, such as blood eosinophil counts or blood periostin levels, have proven important in stratifying asthma patients in clinical trials of type-2 cytokine inhibitors. However, it remains ambiguous how well these non-invasive biomarkers represent airway measures of type-2 inflammation in asthma. As a result, the utility of these biomarkers to assist with asthma management or as research tools to better understand asthma pathogenesis remains unclear. This article reviews primary data assessing biomarkers of airway type-2 inflammation in asthma and describes how the use of biomarkers can advance a precision medicine approach to asthma treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.